Full Pediatric Labeling Is Lacking For One Third Of Orphan Drugs, US FDA Finds

The past three years have seen an increase in number of orphan drug labels containing appropriate pediatric information.

The US Food and Drug Administration’s efforts to improve drug labeling for pediatric patients have been making solid gains in orphan drugs, with the number of orphan products approved with full pediatric labeling hitting a peak in 2015-2018, according to an agency report to Congress.

The FDA analyzed 20 years of orphan drug approvals for the report, which was required by the 2017 FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>